<div id="readability-page-1"><p>TD Cowen analyst Yaron Werber maintained a Buy rating on Kailera Therapeutics, Inc. yesterday. The company’s shares closed yesterday at USD21.57.</p><h3>Memorial Day Sale – Claim 70% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.  </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul> <p>Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Amgen. According to TipRanks, Werber has an average return of <span>24.3%</span> and a 58.70% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kailera Therapeutics, Inc. with a $39.00 average price target, which is an 80.81% upside from current levels. In a report released on May 16, William Blair also maintained a Buy rating on the stock with a $0.00 price target.</p></div>

KLRA

<p>TD Cowen analyst Yaron Werber has reaffirmed a Buy rating on Kailera Therapeutics, Inc. (KLRA), with shares closing at USD21.57. The analyst consensus suggests a Strong Buy rating with an average price target of $39.00, indicating an 80.81% upside. Werber has a 24.3% average return and a 58.70% success rate on his recommendations.</p>

TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)